Video

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Bruno B. Bockorny, MD, attending physician, Gastrointestinal Oncology, Beth Israel Deaconess Medical Center; assistant professor, medicine, Harvard Medical School, discusses findings from a phase 1a/b trial (NCT03860272) with the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034) in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

In this ongoing trial, patients receive botensilimab, a CTLA-4 inhibitor, at 1 mg/kg or 2 mg/kg every 6 weeks plus balstilimab, a PD-1 inhibitor, at 3 mg/kg every 2 weeks. Key end points are the incidence of adverse effects (AEs), overall response rate (ORR), disease control rate (DCR), duration of response, progression-free survival, and overall survival.

The patients evaluable for the safety and efficacy of the combination at the data cutoff had received a median of 4 prior lines of therapy, and high-grade serous ovarian cancer was the most common histologic subtype.

Dr Bockorny on the Efficacy of Botensilimab Plus Balstilimab

The ORR in this heavily pretreated patient population was 33%, with 1 patient achieving a complete response and 7 patients achieving a partial response, Bockorny says. These responses were also durable, Bockorny explains. Additionally, treatment with the combination led to a DCR of 67%.

Dr Bockorny on the Safety Profile of Botensilimab Plus Balstilimab

The safety profile with this combination was as the investigators expected with treatment with a CTLA-4 inhibitor, Bockorny notes. In total, 96% of patients experienced grade 1/2 treatment-related AEs (TRAEs), and 33% and 8% of patients had grades 3 and 4 TRAEs, respectively. The only grade 3/4 AE to occur in more than 1 patient was diarrhea/colitis, and no grade 5 AEs occurred. These higher-grade events were manageable, and no patients experienced pneuomonitis, hypophysitis, or myocarditis of any grade, Bockorny says. Importantly, treatment with botensilimab plus balstilimab led to few high-grade visceral toxicities outside of the gastrointestinal tract, Bockorny concludes. 

Related Videos
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD
Domenica Lorusso, MD, PhD
Martin H. Voss, MD
Jacob Sands, MD